tiprankstipranks
Trending News
More News >
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) AI Stock Analysis

Compare
683 Followers

Top Page

TC

Alaunos Therapeutics

(NASDAQ:TCRT)

Rating:45Neutral
Price Target:
Alaunos Therapeutics' overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.

Alaunos Therapeutics (TCRT) vs. SPDR S&P 500 ETF (SPY)

Alaunos Therapeutics Business Overview & Revenue Model

Company DescriptionAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
How the Company Makes MoneyAlaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing deals with larger pharmaceutical companies. These partnerships can include milestone payments and royalties based on the successful development and commercialization of therapies. Additionally, Alaunos may seek funding through private and public investments to support ongoing research and clinical trials, although these do not directly constitute revenue.

Alaunos Therapeutics Financial Statement Overview

Summary
Alaunos Therapeutics faces significant financial challenges with continuous losses, negative cash flows, and a declining equity base. While the absence of debt reduces financial risk, the lack of profitability and need for external funding highlight the company's precarious financial position.
Income Statement
30
Negative
Alaunos Therapeutics has struggled with profitability, evidenced by its negative net income and EBIT margins over recent years. Despite a marginal increase in revenue in the latest year, the company remains unprofitable, with widening losses. The gross profit margin is effectively non-existent due to minimal revenue.
Balance Sheet
40
Negative
The company has a relatively strong equity position with no debt, reflected in a debt-to-equity ratio of zero. However, its equity ratio has declined due to shrinking stockholders' equity, which signals potential financial instability. Return on equity is not meaningful due to persistent losses.
Cash Flow
35
Negative
Alaunos Therapeutics reports negative free cash flow, indicating cash outflows from operations continue to exceed cash inflows. Although operating cash flow has improved from previous years, the company still requires substantial external financing to support operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue10.00K10.00K5.00K2.92M398.00K0.00
Gross Profit9.00K10.00K-4.80M163.00K-342.00K-1.13M
EBITDA-4.07M-4.68M-30.90M-31.82M-74.97M-78.85M
Net Income-4.07M-4.68M-35.14M-37.60M-76.89M-78.85M
Balance Sheet
Total Assets2.12M2.75M8.26M64.94M94.86M146.34M
Cash, Cash Equivalents and Short-Term Investments319.00K1.09M6.06M39.06M76.05M115.07M
Total Debt0.000.000.0019.51M29.36M4.81M
Total Liabilities1.06M692.00K1.96M26.38M36.81M22.36M
Stockholders Equity1.06M2.06M6.31M38.55M58.06M123.98M
Cash Flow
Free Cash Flow25.85M-4.97M-30.34M-29.45M-64.79M-66.79M
Operating Cash Flow23.61M-4.97M-30.14M-29.23M-61.47M-57.01M
Investing Cash Flow0.000.001.35M-193.00K-3.32M-9.78M
Financing Cash Flow-24.95M0.00-18.14M6.37M25.78M102.12M

Alaunos Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.02
Price Trends
50DMA
2.96
Positive
100DMA
2.39
Positive
200DMA
2.31
Positive
Market Momentum
MACD
0.54
Negative
RSI
76.09
Negative
STOCH
92.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Positive. The current price of 5.02 is above the 20-day moving average (MA) of 3.43, above the 50-day MA of 2.96, and above the 200-day MA of 2.31, indicating a bullish trend. The MACD of 0.54 indicates Negative momentum. The RSI at 76.09 is Negative, neither overbought nor oversold. The STOCH value of 92.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCRT.

Alaunos Therapeutics Risk Analysis

Alaunos Therapeutics disclosed 58 risk factors in its most recent earnings report. Alaunos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Alaunos Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.41B0.32-61.11%2.34%16.99%1.69%
45
Neutral
$3.90M-100.01%6.87%
45
Neutral
$7.39M-139.06%80.00%86.70%
43
Neutral
$5.98M-53.16%-1.56%5.01%
39
Underperform
$3.58M-714.96%978.39%69.65%
29
Underperform
$2.48M-748.05%-100.00%76.55%
28
Underperform
$1.35M-120.01%97.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TCRT
Alaunos Therapeutics
5.02
-2.18
-30.28%
TOVX
Theriva Biologics
0.44
-5.64
-92.76%
SONN
Sonnet BioTherapeutics Holdings
1.15
-6.44
-84.85%
OGEN
Oragenics
3.49
-26.21
-88.25%
WINT
Windtree Therapeutics
0.46
-164.04
-99.72%
XBIO
Xenetic Biosciences
3.99
-0.16
-3.86%

Alaunos Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Alaunos Therapeutics Board Opts for Equity Compensation
Neutral
Apr 15, 2025

On April 13, 2025, Alaunos Therapeutics‘ Board of Directors decided to receive their deferred board service fees in equity instead of cash, as per the company’s policy. The deferred fees, totaling $139,000 from late 2024 to early 2025, were compensated with 38,269 shares of common stock and 10,904 stock options, reflecting a strategic move to align the board’s interests with the company’s performance.

Spark’s Take on TCRT Stock

According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.

Alaunos Therapeutics is in a challenging financial position due to ongoing losses and negative cash flows. While technical indicators suggest positive momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock. The absence of debt provides some financial flexibility, but the need for external funding remains a critical concern.

To see Spark’s full report on TCRT stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025